

WEEKLY FUNDING ALERTS Week of 04.21.11

Featured Funding Opportunities

[Oregon Clinical and Translational Research Institute \(OCTRI\) – Pilot Project Funding for a Collaborative Translational Research Opportunity with the Oregon Translational Research and Drug Development Institute \(OTRADI\)](#)

Description: Facilitates novel, collaborative studies designed to lead commercializable new drugs or diagnostics as the translational outcome. Funding will be awarded on a competitive basis for projects requiring research, screening, assay, or prototype development to ready the project for licensing or potential company start-up.

Deadline: Letter of intent (required): May 4, 2011 / Full application (invitation only): May 30, 2011

Amount: Up to \$75,000.

Eligibility: OHSU Applicants must fit the general guidelines for [PI eligibility](#). Members of OCTRI's leadership team and program directors may not apply for pilot project funding, but applications that build on the work currently being done in OHSU's large and active cohort of existing clinical protocols are encouraged. Members of OTRADI's Board of Directors and/or Scientific Advisory Board and/or investigators currently receiving funding via OTRADI or i6 Challenge Awards are not eligible for funding. Multidisciplinary collaborations pairing investigators from disparate scientific/medical areas are encouraged.

[Pacific Northwest Regional Center of Excellence \(PNWRCE\) – Career Development Awards for Postdoctoral Fellows](#)

Description: The PNWRCE is three-year-old consortium of academic and research institutions in the Pacific Northwest created to advance research on NIH/National Institute of Allergy and Infectious Diseases (NIAID) Category A, B, and C Priority Pathogens and emerging infectious diseases. The goal of this award is to promote rigorous scientific training for postdoctoral fellows performing research on NIAID Group I, II, or III biodefense-related, emerging, or re-emerging pathogens and to encourage investigators in a broad array of disciplines to enter into this research area. Priority will be given to projects that fit within the two main PNWRCE themes:

- (1) The identification of age-related defects in the immune system to facilitate the development of vaccines and supplemental therapies.
- (2) The use of systems biology and systems genetics approaches to define pathogen-host interactions and mechanisms of innate and adaptive immunity.

Deadline: May 6, 2011

Amount: Salary, fringe benefits and supplies for two or three years.

Eligibility: Investigators must have a PhD, DVM, or MD degree, and must be postdoctoral fellows at the time of award with no more than six years of research experience past the award of their doctoral degree. Applicants may be either scientists or clinicians, but the proposed training must entail at least 80% effort on the proposed research project. Applications from minority candidates are strongly encouraged and will be given preference during review.

Department of Defense (DoD) breast cancer research funding opportunities have been reissued.
See "Non-NIH Federal Opportunities" below for links to full announcements.

Non-Federal, Foundation and Corporate Opportunities

OHSU Foundation Tracking and Clearance: Please note all of the following private foundation opportunities require OHSU Foundation clearance, unless otherwise indicated. If you intend to apply, please follow the instructions and complete the OHSU Foundation tracking and clearance form available [here](#).

[Robert Wood Johnson Foundation \(RWJF\) – Public Health Services and Systems Research \(PHSSR\)](#)

Description: Seeks to expand the evidence base for effective public health policy and practice through investment in PHSSR. PHSSR examines the organization, financing and delivery of public health services within a community and determines the links between the quality and performance of the public health system and population health outcomes.

Deadline: Letter of intent: May 24, 2011 / Full application: August 23, 2011

Amount: Up to \$200,000 total for a two-year period.

Eligibility: Applicants may be either public entities or nonprofit organizations or academic institutions that are tax-exempt under Section 501(c)(3) of the Internal Revenue Code. Private foundations as defined under Section 509(a) of the Internal Revenue Code are eligible to apply. Preference will be given to proposals submitted by governmental public health agencies, nonprofit organizations that work in concert with such agencies, and proposals that involve multidisciplinary teams. Applicant organizations must be based in the U.S. or its territories at the time of application. Practitioners, researchers, and policy-makers may serve as PIs. This solicitation seeks to engage new researchers in the field of PHSSR. Researchers who have not previously conducted research in the field of PHSSR are encouraged to apply, and junior investigators (less than seven years since doctorate) and first-time applicants will be strongly considered.

[Robert Wood Johnson Foundation \(RWJF\)/University of Kentucky College of Public Health – Assuring the Future of Public Health Services and Systems Research \(PHSSR\)](#)

UPDATE 5/5/11: “Round VI of the “Assuring the Future of Public Health Systems & Services Research” Mini-Grant Program has been temporarily delayed to allow for a restructuring of the awards program. The re-launch of the program is slated for September 2011 and will feature a streamlined application, review and award process. Our goal of funding promising young investigators who will engage in research using data sets contained in the PHSR subset of Health Services Research Resources (HSRR) will remain unchanged when the program resumes. Stay tuned for updates about the program by following the Coordinating Center for Public Health Services & Systems Research on Facebook, Twitter and LinkedIn, or by becoming a member of our website, publichealthsystems.org. For more information, please contact Jay Swacker at (859)218-6586 or PHSSR212@uky.edu.”

[The Doctors Cancer Foundation – Research Grants](#)

- **Research Grant** – Provides seed money to young investigators for the best genetic, epigenetic or immunologic research projects seeking to find new principles of cancer management. The Foundation encourages scientists to identify and explore untested forms of treatment and ultimately enhance the quality of care for the people who have cancer. There is a strong interest in cancer stem cells, microRNAi agents, epigenetic agents, as well as many others. The foundation is particularly interested in promoting the best of the young scientists, currently under the radar screen. The project should be innovative, sound and be able to lead to clinical trials. || **Amount:** \$50,000 for one year.
- **Nolan Miller Grant** – Provides seed money to young investigators for the best genetic, epigenetic or immunologic supporting research projects seeking to find new principles of lung cancer management. There is a strong interest in cancer stem cells, microRNAi agents, epigenetic agents, as well as many others. The Foundation is particularly interested in promoting the best of the young scientists, currently under the radar screen. The project should be innovative, sound and be able to lead to clinical trials. || **Amount:** \$50,000 for one year.

Deadline: June 30, 2011

Eligibility: No specific eligibility requirements are outlined, however most grants are given to experienced researchers with track records of success. More often than not, funding builds on existing treatments such as chemotherapy, or is used as “overhead” or general support for a university or medical center.

[Oncology Nursing Society \(ONS\) Foundation – Lung Cancer Research Grant](#)

Description: Submissions are invited for lung cancer grant proposals that address innovative areas of research that may include chemoprevention, blood/sputum screening, symptom management, disease progression, as well as high-priority topic areas identified by the [2009 – 2013 ONS Research Agenda](#).

Deadline: Letter of intent: July 18, 2011 / Full application: August 15, 2011

Amount: \$25,000 per year for two years.

Eligibility: The PI must be actively involved in some aspect of cancer patient care, education, or research. Funding preference is given to projects that involve nurses in the design and conduct of research activity. Membership in ONS is not required for eligibility. ONS encourages advanced practice nurse (APN) and researcher partnerships. For an APN PI to be considered for funding the research team must include both an APN and researcher. To be considered for funding, the research team must include an experienced researcher and a junior researcher. The inclusion of an advanced practice nurse on the team is encouraged. Interdisciplinary research teams are encouraged.

NIH Federal Opportunities

OHSU IS NOW ENFORCING THE POLICY REQUIRING NIH GRANTS TO BE SUBMITTED THREE BUSINESS DAYS PRIOR TO THEIR DUE DATE: Starting with the January 25, 2011 deadline, you must submit your final NIH applications to [Research Grants and Contracts](#) (RGC, the pre-award office at OHSU) three business days before their due date. This enforcement is being implemented because the NIH, AHRQ, and NIOSH have eliminated their “error correction window” as of this date. View the [NIH notice](#) for more information.

[Clinical Hematology and Transfusion Medicine Research Career Development Program \(K12\)](#)

Description: The purpose of this program is to develop and evaluate multidisciplinary career development programs in non-malignant hematology and transfusion medicine that will equip new investigators with the knowledge and skills to address complex problems in blood diseases and transfusion medicine. Through this Program, the National Heart, Lung, and Blood Institute (NHLBI) will support the early career development of clinical researchers who are expected to become independent investigators and assume academic leadership roles in non-malignant clinical hematology and transfusion medicine.

Deadline: Internal: May 13, 2011 / External: June 20, 2011

Amount: \$370,000 per year for five years.

Eligibility: *Limited submission* – See below and full announcement. Only one application per institution is allowed. The applicant institution and affiliated organizations should: have a history of clinical research in transfusion medicine and non-malignant blood diseases; have facilities for research in pediatric, adolescent and adult patients; and ensure that Scholars will commit a minimum of 9 person months of full-time professional effort (equivalent to 75% effort) on research career development activities in hematology or transfusion medicine.

Limited Submission: *Please note this opportunity requires internal coordination since OHSU may submit only one application. If you intend to apply, complete a limited submission form at <http://ozone.ohsu.edu/research/rda/funding/limsubform.php> before the internal deadline.*

[National Institute of Allergy and Infectious Diseases \(NIAID\) – An Integrated Approach to Understanding Host-Pathogens Interactions](#)

Description: The Division of Microbiology and Infectious Diseases, NIAID, has a requirement to establish multi-disciplinary centers that focus on understanding at a molecular level the host-pathogen interaction using a systems biology approach. The primary goal of the activities carried out under this contract will be to investigate and identify the metabolic, regulatory, signaling, and other biological pathways generated by host-pathogen molecular interactions to help explain and predict clinical manifestations of infectious diseases, host responses, disease progression, and outcomes. Studies will focus on persistent or recurrent infections with well-defined, highly-specific phenotypes. Examples of such infections include, for example, tuberculosis, malaria, leishmaniasis, histoplasmosis, and infections caused by cytomegalovirus, Epstein-Barr virus, herpes virus, Salmonella spp., Group A streptococci, and Chlamydia trachomatis. Although a systems biology approach could be used to investigate complex biological events, such as cell behavior or microbial communities, the focus of this contract is only on molecular cellular events of the interaction of the pathogen and the host, such as those involved in the biological, biochemical and

biophysical processes of microbial organisms or in pathogenesis and disease progression in humans.

Deadline: June 6, 2011

Amount: Not specified.

Eligibility: Not specified.

Predictive Multiscale Models for Biomedical, Biological, Behavioral, Environmental and Clinical Research (Interagency U01)

Description: The goal of this interagency funding opportunity is to support the development of multiscale models to accelerate biological, biomedical, behavioral, environmental and clinical research. The NIH, Department of Energy, Food and Drug Administration, and National Science Foundation recognize that to efficiently and effectively address the challenges of understanding multiscale biological and behavioral systems, researchers will need predictive, computational models that encompass multiple biological and behavioral scales. This opportunity also encourages the development of new, non-standard modeling methods and experimental approaches to facilitate multiscale modeling.

Deadline: June 17, 2011; September 27, 2011; January 31, 2012; May 31, 2012; September 27, 2012; January 31, 2013; May 31, 2013, September 27, 2013; January 31, 2014

Amount: \$200,000 to \$400,000 per year for five years.

Cardiovascular Cell Therapy Research Network (CTRN) – Multiple Opportunities

Description: The goal of the CCTRN is to promote evaluation of novel cell-based treatment strategies for individuals with cardiovascular disease. The network provides support to maintain an infrastructure to develop, coordinate, and conduct multiple collaborative clinical trials designed to improve cardiovascular disease outcomes.

- **Data Coordinating Center for the CCTRN (UM1)** – The Data Coordinating Center leads and manages all aspects of the conduct of multicenter trials, including site contracts with core laboratories, regulatory compliance, recruitment monitoring, patient safety and adverse event reporting, protocol development, manuals of operations, and training. The Data Coordinating Center also provides a data management function, with expertise in statistical analyses in support of protocol development and manuscript preparation, database development, data collection, quality, and integrity. || **Amount:** Up to \$1.5 million per year for seven years.
- **Regional Clinical Centers for the CCTRN (UM1)** – Regional Clinical Centers participate in development and implementation of network studies, recruit patients and disseminate research findings. The Regional Clinical Center must have demonstrated excellence in performing clinical research in general, with a strong background in both basic and clinical cardiovascular research, and a proven ability to recruit patients with cardiovascular disease from various racial and ethnic groups. Regional Clinical Centers will propose, develop, and conduct protocols, recruit patients, and disseminate research findings. Each Regional Clinical Center will be expected to take part in multiple concurrent protocols and participate in a cooperative and interactive manner with other Regional Clinical Centers and the Data Coordinating Center. Awards may be restricted at sites unable to successfully participate in network protocols and meet patient enrollment goals. || **Amount:** Up to \$300,000 per year for seven years.

Deadline: June 22, 2011

Eligibility: Eligible PIs include those with the experience and expertise to conduct clinical studies in cardiovascular diseases. The disciplines and expertise that may be appropriate for this program are cardiology, cardiovascular surgery, cardiovascular imaging, cardiovascular nursing, cardiovascular physiology, stem cell biology, clinical trials management, project management, regulatory affairs and biostatistics. To ensure that data analysis is performed independently of data acquisition, the PI for a Data Coordinating Center may not be a PI for a Regional Clinical Center, and vice-versa. The same institution may apply for both a Regional Clinical Center and Data Coordinating Center award, but the applications must identify different and independent groups of investigators for each.

Beyond HAART: Innovative Therapies to Control HIV-1 (P01)

Description: The National Institute of Allergy and Infectious Diseases (NIAID) and the National Institute of Mental Health (NIMH) solicit applications to develop therapeutic approaches that could allow HIV-1 infected persons to discontinue current HIV-1 treatments for a sustained period without viral rebound. Approaches of interest include therapeutic vaccines, gene therapies, cell therapies, antibodies, and other targeted interventions. Awardees will perform basic research on the chosen approach, as well as engage in translational activities such as test-of-concept studies in animal models or

humans. Research program project applications must be designed as collaborative efforts between academia and the private sector.

Deadline: July 19, 2011

Amount: Varies – See full announcement.

Eligibility: The multiple PIs option may be used only for the overall program project. The multiple PIs option is not available for the leadership roles of the individual research projects or cores within the program project application.

Cutting-Edge Basic Research Awards (CEBRA) (R21)

Description: Fosters highly innovative or conceptually creative research related to drug abuse and addiction and how to prevent and treat them. It supports research that is high-risk and potentially high-impact that is underrepresented or not included in National Institute on Drug Abuse (NIDA) current portfolio. The proposed research should: (1) test a highly novel and significant hypothesis for which there is scant precedent or preliminary data and which, if confirmed, would have a substantial impact on current thinking; and/or (2) develop or adapt innovative techniques or methods for addiction research, or that have promising applicability to drug abuse research.

Deadline: August 19, 2011; December 21, 2011

Amount: Varies – See full announcement.

Institutional Training for a Dental and Craniofacial Research Workforce (T90/R90) & Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Training for a Dental and Craniofacial Research Workforce (T32)

Description: For institutions that are committed to supporting predoctoral and postdoctoral training in dental, oral, and craniofacial research. This program is designed in recognition of the need to develop a cadre of highly qualified independent scientists who can successfully address basic, behavioral, and clinical research questions to improve oral, dental, and craniofacial health. Priority will be given to programs that present plans and evidence that they will train dentist scientists either as predoctoral dual degree dentist scientists, dentists receiving PhD training or dentists training in a postdoctoral research experience.

Deadline: September 25, 2011; September 25, 2012

Amount: Up to \$800,000 per year for up to five years.

Eligibility: Eligible institutions include dental schools and other institutions that have strong and high quality programs in dental, oral and craniofacial research, and which have the requisite staff and facilities on site to conduct the proposed research training program. Additional eligibility requirements apply – See full announcements for additional information.

Early-Phase Clinical Trials for Blood Cell Therapies (R01) Early-Phase Clinical Trials for Blood Cell Therapies (R01)

Description: The National Heart, Lung, and Blood Institute (NHLBI) encourages research project grant applications for the purpose of supporting early-phase clinical trials—*i.e.*, first-in-human, phase I, or phase II trials—to evaluate innovative and novel cell therapies to treat blood diseases and/or to improve the outcome of hematopoietic stem cell transplantations.

Deadline: October 5, 2011; October 5, 2012

Amount: Varies – See full announcement.

Alcohol Education Project Grants (R25)

Description: The National Institute on Alcohol Abuse and Alcoholism (NIAAA) supports research programs to advance understanding of the biological and behavioral processes involved in the development, expression, and consequences of alcoholism and other alcohol-related problems. The Institute also supports prevention, treatment, and health services research on alcohol abuse and alcoholism. A part of the NIAAA mission is the dissemination of new knowledge acquired from alcohol research to diverse audiences, including scientists, educators, clinicians, and other health and social service providers, patients and their families, professionals within the criminal justice system, and the general public.

Deadline: Standard dates apply – See full announcement.

Amount: Up to \$250,000 per year for two years.

Non-NIH Federal Opportunities

Department of Defense (DoD) – Breast Cancer Research Opportunities

Description: The Breast Cancer Research Program (BCRP) challenges the scientific community to design innovative, high-impact research that will address critical issues and foster new directions toward the vision of eradicating breast cancer. The BCRP promotes unique partnerships and multidisciplinary collaborations that will accelerate advances in breast cancer research. In addition, the BCRP supports training the next generation of breast cancer investigators through mentored research. The BCRP seeks applications from all areas of basic, translational, clinical, behavioral, and epidemiological research. Applications focused on understudied areas, such as breast cancer prevention and health disparities, are encouraged.

- **Breast Cancer Idea Award** – Designed to support promising research that has extraordinary potential to yield highly impactful data and new avenues of investigation. This mechanism supports innovative research that could ultimately lead to critical discoveries or major advances that will accelerate the eradication of breast cancer. The Idea Award mechanism encourages applications that include meaningful and productive collaborations between investigators. A Partnering PI Option under the Idea Award mechanism is available to accommodate two PIs, with each under a separate award. See the full announcement for more information. || **Deadline:** Pre-application (required): May 31, 2011 / Full application (invitation only): August 25, 2011 || **Amount:** \$250,000 per year for two years. || **Eligibility:** Investigators at all academic levels are eligible to submit an application. Each individual may submit only one pre-application as PI or Initiating PI.
- **Breast Cancer Transformative Vision Award** – Supports research projects to realize an extraordinary vision for dramatically affecting the prevention or treatment of breast cancer, and plan to test and achieve the vision as quickly as possible through the translation of these ideas into patients. The scope of this effort may include a broad spectrum of research spanning from basic to clinical studies. The Transformative Vision Award will be supported in two phases. Phase I (Years 1-2) will enable the team to lay the groundwork for the research project and to test the basic concepts of the vision. Phase II (Years 3-5) will allow the expansion of the project to proceed to accomplishment of the vision. Before moving from Phase I to Phase II, the PI and his/her team will be required to present an update on progress toward accomplishing the goals of the project at a 1-day Milestone Meeting to be held in the Baltimore/Washington, DC area. || **Deadline:** Pre-application (required): May 31, 2011 / Full application (invitation only): August 25, 2011 || **Amount:** \$250,000 per year for two years. || **Eligibility:** The research team must include two or more breast cancer consumer advocates who will be integrally involved throughout the planning and implementation of the research project. Consumer advocates should be involved in the identification of the research question, project design, oversight, recruitment, and evaluation, as well as other significant aspects of the proposed project. PIs must be at or above the level of assistant professor.
- **Postdoctoral Fellowship Award Grant** – Supports exceptionally talented recent doctoral or medical graduates in their pursuit of innovative, high-impact breast cancer research during their postdoctoral training, and allows them to obtain the necessary experience for an independent career at the forefront of breast cancer research. || **Deadline:** Pre-application (required): June 7, 2011 / Full application: June 21, 2011 || **Amount:** \$100,000 per year for three years. || **Eligibility:** Eligible PIs must have successfully completed the requirements for a doctoral or medical degree; have been in a laboratory or clinical research setting in which the proposed research is to be performed for no more than two years as a postdoctoral researcher; and have a total of less than four years of postdoctoral research experience (excluding clinical residency or fellowship training).
- **Breast Cancer Innovator Award** – Supports visionary individuals who have demonstrated creativity, innovative work, and leadership in any field including, but not limited to breast cancer. This award will provide individuals who with funding and freedom to pursue their most novel, visionary, high-risk ideas that could ultimately lead to the eradication of breast cancer. || **Deadline:** Pre-application (required): June 7, 2011 / Full application: June 21, 2011 || **Amount:** \$1 million per year for five years. || **Eligibility:** PIs must be at or above the associate professor level.
- **Breast Cancer Era for Hope Scholar Award** – Supports individuals who are early in their careers and have high potential for innovation in breast cancer research. These individuals

should be exceptionally talented scientists who have demonstrated that they are the “best and brightest” in their field(s) through extraordinary creativity, vision, and productivity. They should have demonstrated experience in forming effective partnerships and collaborations and should exhibit strong potential for leadership in the breast cancer research community. || **Deadline:** Pre-application (required): June 7, 2011 / Full application: June 21, 2011 || **Amount:** \$500,000 per year for five years. || **Eligibility:** Experience in breast cancer research is not required; however, the application must focus on breast cancer, and the PI must commit at least 50% of his/her full-time professional effort during the award period to breast cancer research. PIs must be independent, non-mentored investigators within six years of their last mentored position.

[Department of Defense \(DoD\) – Clinical Trial Award in Regenerative Medicine, Pain, and Sensory System](#)

Description: Supports early phase clinical trials with the potential to have a major impact on treatment of combat-related injuries in the areas of pain, restoration of sensory systems (balance, hearing, and vision), and regenerative medicine technologies. All studies must be responsive to the health care needs of military service members and veterans, and all applications must specifically and clearly address the military relevance of the proposed research; however, the use of military populations in the clinical trial is not a requirement. Proposed projects should be designed to demonstrate the safety and efficacy of novel therapies and diagnostics in human patients suffering from serious, debilitating injuries of the extremities, skin, sensory systems, or craniomaxillofacial area due to trauma. The purpose of such demonstrations is to accelerate translation of greater medical capabilities to patients; this can range from proof of concept (i.e. first in human or Phase 0) trials through Phase II clinical trials, as well as Class I, II, or III device trials. Phase III clinical trials are not allowed. Projects of interest are those focused on testing and translating investigational interventions already proven in relevant definitive animal models, moving them into advanced clinical development.

Deadline: Pre-application (required): June 1, 2011 / Full application (invitation only): August 25, 2011

Amount: \$500,000 per year for four years.

Eligibility: Funding from this award mechanism must support a clinical trial and cannot be used for preclinical research studies. Independent investigators at any academic level may submit applications.

[Food and Drug Administration \(FDA\) – Analgesic Clinical Trials Innovation, Opportunities, and Networks \(ACTION\) Initiative \(U01\)](#)

Description: Provides support for developing and maintaining an organizational infrastructure to support a broad-based public-private partnership under the FDA’s ACTION initiative, which aims to streamline the discovery and development process for new analgesic drug products for the benefit of public health.

Deadline: June 8, 2011

Amount: Varies – See full announcement.

Eligibility: An eligible organization that wishes to enter into a collaborative agreement must provide an assurance that the entity will not accept funding for a Critical Path Public-Private Partnership project from any organization that manufactures or distributes products regulated by the Food and Drug Administration unless the entity provides assurances in its agreement with the Food and Drug Administration that the results of the Critical Path Public-Private Partnership project will not be influenced by any source of funding.

Plan Ahead: Anticipated Funding Opportunities

Sponsor	Opportunity Type(s)
Department of Defense (DoD) <i>New</i>	Autism Research Program: Clinical Trial Award, Idea Development Award, Pilot Award
NIH – National Institute on Deafness and Other Communication Disorders <i>New</i>	Request for Applications for Research on Hearing Health Care (R21/R33)
NIH – National Institute of Neurological Disorders and Stroke (NINDS)	Request for Applications for a Spinal Muscular Atrophy (SMA) Biomarker Study (U01) and Convene a Related Workshop
NIH – National Cancer Institute (NCI)	Cancer Target Discovery and Development (CTDD) Initiative (U01)
NIH – Fogarty International Center (FIC)	International Tobacco and Health Research and Capacity Building Program (TOBAC) (R01)
NIH – Multiple Institutes	Biomedical/Biobehavioral Research Administration Development (BRAD) Award (G11)
NIH – Fogarty International Center (FIC)	Framework Programs for Global Health/Innovations (R24)
NIH – Fogarty International Center (FIC)	Funding Opportunity to Restructure the Fogarty International Clinical Research Training for Scholars and Fellows Program (FICRS-F) (R24)
NIH – Multiple Institutes	Autism Centers of Excellence (R01 Network)
NIH – Multiple Institutes	Autism Centers of Excellence (P50 Centers)
NIH – National Institute on Drug Abuse (NIDA)	Integration of Drug Abuse Prevention and Treatment in Primary Care Settings (R01)
Department of Defense (DoD)	Prostate Cancer Research Program: Clinical Trial Award, Exploration-Hypothesis Development Award, Health Disparity Research Award, Idea Development Award, Impact Award, Laboratory-Clinical Transition Award, Population-Based Research Award, Synergistic Idea Development Award, Health Disparity Training Award, Physician Research Training Award, Postdoctoral Fellowship Award
Department of Defense (DoD)	Neurofibromatosis Research Program: Clinical Consortium Award, Clinical Trial Award, Exploration-Hypothesis Development Award, Investigator-Initiated Research Award, Investigator-Initiated Focused Research Award, New Investigator Award, Postdoctoral Traineeship
Department of Defense (DoD)	Tuberous Sclerosis Complex Research Program: Career Transition Award, Clinical Trial Award, Exploration-Hypothesis Development Award, Idea Development Award
Department of Defense (DoD)	Gulf War Illness Research Program: Investigator-Initiated Research Award, Innovative Treatment Evaluation Award, Clinical Trial Award, Clinical Trial Development Award

Stay tuned for more specific information. We will post details as they are released by the funding agency.